The story of the erectile dysfunction drug presents a intricate picture for shareholders. While the initial introduction generated massive gains, the expiration of its patent opened the door to off-brand versions, dramatically diminishing sales. This creates a particular challenge for drug manufacturers depending on related blockbuster products, su

The legacy of Viagra, and its developer copyright, presents a intriguing case study for investors. At first a blockbuster drug, generating billions in income, its exclusivity period created a flood of knock-off medications, significantly impacting its position . While certain pharmaceutical companies may try to capitalize on related treatments , th